Biological Assembly 1  

 3D View: Structure | Electron Density | Ligand Interaction

Global Symmetry: Dihedral - D2  (3D View)
Global Stoichiometry: Homo 4-mer - A4 

Biological assembly 1 assigned by authors.

Macromolecule Content

• Total Structure Weight: 28.29 kDa 
• Atom Count: 2055 
• Residue Count: 229 
• Unique protein chains: 1

3IMV

Transthyretin in complex with (E)-4-(4-aminostyryl)-2,6-dibromoaniline

• DOI: 10.2210/pdb3IMV/pdb

• Classification: HORMONE
• Organism(s): Homo sapiens
• Expression System: Escherichia coli
• Mutation(s): No 


• Deposited: 2009-08-11 Released: 2010-01-12 
• Deposition Author(s): Connelly, S., Wilson, I.A.

---

Experimental Data Snapshot

• Method: X-RAY DIFFRACTION
• Resolution: 1.47 Å
• R-Value Free: 0.201 
• R-Value Work: 0.168 
• R-Value Observed: 0.169 

Literature

A substructure combination strategy to create potent and selective transthyretin kinetic stabilizers that prevent amyloidogenesis and cytotoxicity.

Choi, S., Reixach, N., Connelly, S., Johnson, S.M., Wilson, I.A., Kelly, J.W.

(2010) J Am Chem Soc 132: 1359-1370

• PubMed: 20043671 
• DOI: 10.1021/ja908562q
• Primary Citation of Related Structures:  
  3IMR, 3IMS, 3IMT, 3IMU, 3IMV, 3IMW


• PubMed Abstract: 
  

Transthyretin aggregation-associated proteotoxicity appears to cause several human amyloid diseases. Rate-limiting tetramer dissociation and monomer misfolding of transthyretin (TTR) occur before its aggregation into cross-beta-sheet amyloid fibrils. Small molecule binding to and preferential stabilization of the tetrameric state of TTR over the dissociative transition state raises the kinetic barrier for dissociation, imposing kinetic stabilization on TTR and preventing aggregation. This is an effective strategy to halt neurodegeneration associated with polyneuropathy, according to recent placebo-controlled clinical trial results. In three recent papers, we systematically ranked possibilities for the three substructures composing a typical TTR kinetic stabilizer, using fibril inhibition potency and plasma TTR binding selectivity data. Herein, we have successfully employed a substructure combination strategy to use these data to develop potent and selective TTR kinetic stabilizers that rescue cells from the cytotoxic effects of TTR amyloidogenesis. Of the 92 stilbene and dihydrostilbene analogues synthesized, nearly all potently inhibit TTR fibril formation. Seventeen of these exhibit a binding stoichiometry of >1.5 of a maximum of 2 to plasma TTR, while displaying minimal binding to the thyroid hormone receptor (<20%). Six analogues were definitively categorized as kinetic stabilizers by evaluating dissociation time-courses. High-resolution TTR.(kinetic stabilizer)(2) crystal structures (1.31-1.70 A) confirmed the anticipated binding orientation of the 3,5-dibromo-4-hydroxyphenyl substructure and revealed a strong preference of the isosteric 3,5-dibromo-4-aminophenyl substructure to bind to the inner thyroxine binding pocket of TTR.

---

Organizational Affiliation: 

Department of Chemistry, The Skaggs Institute for Chemical Biology, La Jolla, California 92037, USA.

Macromolecules

Entity ID: 1
Molecule	Chains	Sequence Length	Organism	Details	Image
Transthyretin	A, B	127	Homo sapiens	Mutation(s): 0  Gene Names: TTR, PALB
Find proteins for P02766 (Homo sapiens) Explore P02766  Go to UniProtKB:  P02766
NIH Common Fund Data Resources
PHAROS  P02766 GTEx  ENSG00000118271

Small Molecules

Ligands 1 Unique
ID	Chains	Name / Formula / InChI Key	2D Diagram
IW5	A, B	4-[(E)-2-(4-aminophenyl)ethenyl]-2,6-dibromoaniline C14 H12 Br2 N2 JADLJYGSTKXGCQ-OWOJBTEDSA-N

Experimental Data & Validation

Experimental Data

• Method: X-RAY DIFFRACTION
• Resolution: 1.47 Å
• R-Value Free: 0.201 
• R-Value Work: 0.168 
• R-Value Observed: 0.169 
• Space Group: P 2₁ 2₁ 2

Unit Cell:

Length ( Å )	Angle ( ˚ )
a = 42.781	α = 90
b = 85.169	β = 90
c = 64.158	γ = 90

Software Package:

Software Name	Purpose
REFMAC	refinement
PDB_EXTRACT	data extraction
Blu-Ice	data collection
HKL-2000	data reduction
HKL-2000	data scaling
PHASER	phasing

Structure Validation

Entry History 

Deposition Data

• Deposited Date: 2009-08-11 
• Released Date: 2010-01-12 
Deposition Author(s): Connelly, S., Wilson, I.A.

Revision History 

• Version 1.0: 2010-01-12
  Type: Initial release
  
• Version 1.1: 2011-07-13
  Changes: Version format compliance